Different effects of chronic administration of haloperidol and pimozide on dopamine metabolism in the rat brain.
We investigated the differences between the action of haloperidol and pimozide on dopamine metabolism and on catalepsy in periods up to 6 weeks after cessation of chronic administration of the neuroleptics to male Wistar rats. Dopamine and its metabolites (dihydroxyphenylacetic and homovanillic acids) were measured, using high-performance liquid chromatography (HPLC), in the frontal cortex, nucleus accumbens, and striatum. Both neuroleptics produced similar effects after a single dose: catalepsy and an increase of dopamine metabolism in the brain structures. However, haloperidol and pimozide differed after chronic treatment. In haloperidol-treated rats hypersensitivity of the dopaminergic system developed at the end of 2 weeks' administration, as evidenced by depression of dopamine metabolism. The biochemical changes were accompanied by behavioral hyperactivity that lasted up to 3 weeks. Dopamine metabolism in rats treated with pimozide was normal from 24 h after the end of the treatment, while catalepsy was maintained at the high level for up to 8 days and was observable up to 3 weeks after the last dose. Our results suggest that in contrast to haloperidol, pimozide is not able to produce adaptive changes leading to supersensitivity of the dopaminergic system. This may be the consequence of its potent Ca2+ channel blocking action.
Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland.
B
B
Karolewicz
L
L
Antkiewicz-Michaluk
J
J
Michaluk
J
J
Vetulani
D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects* / Q000378:metabolism*; D002375:Catalepsy / Q000139:chemically induced; D004298:Dopamine / Q000378:metabolism*; D004334:Drug Administration Schedule; D005116:Extrapyramidal Tracts / Q000187:drug effects / Q000378:metabolism; D006220:Haloperidol / Q000494:pharmacology*; D008032:Limbic System / Q000187:drug effects / Q000378:metabolism; D008297:Male; D010868:Pimozide / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D013375:Substance Withdrawal Syndrome / Q000209:etiology / Q000378:metabolism
D014150:Antipsychotic Agents; D010868:Pimozide; D006220:Haloperidol; D004298:Dopamine